26th Conference of the Asian Pacific Association for the Study of the Liver (APASL)

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

26th Conference of the Asian Pacific Association for the Study of the Liver (APASL)

15 February 2017 - 19 February 2017

Decision making in hepatitis B: Q&A with hepatologist Prof Anna Lok

Pearl Toh, 20170309100500

Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Add-on pegIFN may be better than total switch for Hep B on NUCs

Add-on vs switch to pegIFN better for Hep B on NUCs

Pearl Toh, 20170308100500

Add-on of pegylated interferon (pegIFN) to nucleos(t)ide analogues (NA) therapy may be a better strategy than a switch from NA to pegIFN in patients with chronic hepatitis B (CHB) who are on long-term NA therapy, according to data from an interim analysis of the SWAP* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.

Poorer outcomes in cryptogenic hepatocellular carcinomas vs other aetiologies

Tristan Manalac, 20170225100000

Compared with viral hepatocellular carcinomas and those of other aetiologies, cryptogenic hepatocellular carcinomas tend to manifest at later stages and are associated with worse survival, according to a study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017).

[APASL 2017]: Updates on pharmacological approach to managing portal hypertension

Pearl Toh, 20170224100500

The goal of treatment for portal hypertension varies depending on the different stages and substages of cirrhosis, and hence, pharmacological therapies for managing portal hypertension should be considered in the context of other complications of cirrhosis, according to a presentation at the recent APASL 2017 held in Shanghai, China recently.

Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL)

20170224054512

Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.

Statin use associated with lower risk of pyogenic liver abscess

Roshini Claire Anthony, 20170223140600

The use of statins is associated with a lower risk of pyogenic liver abscess, according to a Taiwan population-based case-control study.

Statin therapy may reduce cirrhosis and its decompensation in CHB patients

Elaine Soliven, 20170223091126

Statin therapy may reduce the risk of cirrhosis and its associated comorbidities in chronic hepatitis B (CHB) patients, according to a presentation at the 26^th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2017 held in Shanghai, China.

Hepatitis C patients who achieve SVR have reduced fibrosis, HCC risk

Roshini Claire Anthony, 20170222140200

Individuals with hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) have improved liver stiffness and a lower risk of hepatocellular carcinoma (HCC), according to a presentation at the Asian Pacific Association for the Study of the Liver annual meeting (APASL 2017) in Shanghai, China.

C-ISLE: Elbasvir/grazoprevir plus sofosbuvir highly effective against HCV genotype 3

Jairia Dela Cruz, 20170222100000

An 8- to 16-week treatment regimen of elbasvir/grazoprevir plus sofosbuvir with or without ribavirin appears to be highly effective and well tolerated in both treatment-naïve and treatment-experienced cirrhotic patients with hepatitis C virus (HCV) genotype 3 (GT3) infection, according to the results of the C-ISLE study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Shanghai, China.

Persistently elevated serum TBA ups risk of hepatocellular carcinoma development

Stephen Padilla, 20170222084322

Persistently elevated serum total bile acid (TBA) may increase the risk of developing hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with regular antiviral treatment, according to a study presented at the 26th Conference of Asian Pacific Association for the Study of the Liver (APASL) in Shanghai, China.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

Switching to ixazomib-based induction feasible, effective in newly diagnosed multiple myeloma

Stephen Padilla, 12 Dec 2019

Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

FLAG-GO vs FLAG-Ida regimen leads to better relapse-free survival in CBF acute myeloid leukaemia

Stephen Padilla, 16 Dec 2019

Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.

Daratumumab add-on to RVd boosts response rates in transplant-eligible NDMM

Elaine Soliven, 17 Dec 2019

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.